Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2026)

Lyell Immunopharma has reported Long-Term Investments for 7 years, with the latest figure at $7.0 million in Q1 2026.

• Quarterly Long-Term Investments fell 63.4% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 63.4% YoY) and the FY2024 annual result came in at $13.0 million, down 59.33% from the prior year.
• Long-Term Investments fell to $7.0 million in Q1 2026 per LYEL's latest filing, from $19.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $47.0 million in Q1 2022 and troughed at $7.0 million in Q1 2026.
• A 5-year average of $26.6 million and a median of $19.0 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments sank 78.72% in 2023, then soared 90.0% in 2024.
• Over 5 years, Long-Term Investments stood at $44.9 million in 2022, then declined by 28.77% to $32.0 million in 2023, then tumbled by 59.33% to $13.0 million in 2024, then soared by 46.0% to $19.0 million in 2025, then slumped by 63.4% to $7.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $7.0 million, $19.0 million, and $19.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.